The development of DNA microarray and RNA-sequencing technology has led to an explosion in the generation of transcriptomic differential expression data under a wide range of biologic systems including those recapitulating the monogenic muscular dystrophies. Data generation has increased exponentially due in large part to new platforms, improved cost-effectiveness, and processing speed. However, reproducibility and thus reliability of data remain a central issue, particularly when resource constraints limit experiments to single replicates. This was observed firsthand in a recent rare disease drug repurposing project involving RNA-seq-based transcriptomic profiling of primary cerebrocortical cultures incubated with clinic-ready blood–brain penetrant drugs. Given the low validation rates obtained for single differential expression genes, alternative approaches to identify with greater confidence genes that were truly differentially expressed in our dataset were explored. Here we outline a method for differential expression data analysis in the context of drug repurposing for rare diseases that incorporates the statistical rigour of the multigene analysis to bring greater predictive power in assessing individual gene modulation. Ingenuity Pathway Analysis upstream regulator analysis was applied to the differentially expressed genes from the Care4Rare Neuron Drug Screen transcriptomic database to identify three distinct signaling networks each perturbed by a different drug and involving a central upstream modulating protein: levothyroxine (DIO3), hydroxyurea (FOXM1), dexamethasone (PPARD). Differential expression of upstream regulator network related genes was next assessed in in vitro and in vivo systems by qPCR, revealing 5× and 10× increases in validation rates, respectively, when compared with our previous experience with individual genes in the dataset not associated with a network. The Ingenuity Pathway Analysis based gene prioritization may increase the predictive value of drug–gene interactions, especially in the context of assessing single-gene modulation in single-replicate experiments.
1 July 2015 in Degenerative Neurological and Neuromuscular Disease
Spinal muscular atrophy is one of the most common inherited neuromuscular conditions; our understanding of the genetic pathology and translational research coming from this insight has made significant progress over the past decade. This short review provides the background of the disease along with the bench to bedside progress of some promising treatment options to develop better understanding of the present state of the disease.
Background: Spinal muscle atrophy (SMA) is an autosomal recessive neurodegenerative disease which is characterized by the loss of α motor neurons resulting in progressive muscle atrophy (1). The loss of functional Survival motor neuron (SMN) protein due to mutations or deletion in the SMN1 gene is the cause of SMA (2). Method: A potential treatment strategy for SMA is to upregulate levels of the SMN protein originating from the copy gene SMN2 which could compensate in part for the absence of the functional SMN1 gene (3-5). Goal of the study and Results: We have shown a novel therapeutic strategy for SMA treatment through the activation of the p38 and STAT5 kinase pathway activating clinic ready compounds (6, 7). Celecoxib (p38 activating drug) and Prolactin (STAT5 activator) demonstrate a clear promise for use in SMA clinical trial studies as they increase SMN protein levels, ameliorate disease phenotype in SMA mouse model, have blood brain barrier penetration and also have FDA approved status (6, 8). We have also identified other clinic ready STAT5 and p38 pathway activators as new candidates for SMA treatment (9, 10). These results provide evidence and need for FDA approved compound library screen to identify clinic ready compounds for the treatment of SMA. Conclusion: SMA is a deadly neurodegenerative disease with a prevalence of 1:10000 mostly affecting children and more than 50% affected children die before the age of two (11-16). It is the most common genetic cause of infant death and is currently untreatable (15). This study will help in the identification of clinic ready compounds as new candidates for SMA treatment which will provide us an excellent platform to extend this approach on a wider scale to other rare disorders. We believe it shall bring effective treatments closer to reality for rare genetic disorders.